Cartesian reports Descartes-08 Phase 2b MG data: sustained 12-month benefit, Phase 3 on track

Cartesian Therapeutics, Inc.

Average MG-ADL reduction of 4.8 points at Month 12; 83% maintained clinically meaningful response.
In biologic-naive subgroup (n=7): avg 7.1-point MG-ADL reduction, 57% achieved minimum symptom expression (MG-ADL 0-1) at Month 12.
No new safety signals; no CRS or ICANS; supports outpatient administration without lymphodepleting chemo.
Phase 3 AURORA trial on track to dose first patient in Q2 2025; FDA SPA agreement for trial design.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.